BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36610667)

  • 1. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis.
    Palipana AK; Gecili E; Song S; Johnson SR; Szczesniak RD; Gupta N
    Chest; 2023 Jun; 163(6):1458-1470. PubMed ID: 36610667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis.
    Gupta N; Lee HS; Ryu JH; Taveira-DaSilva AM; Beck GJ; Lee JC; McCarthy K; Finlay GA; Brown KK; Ruoss SJ; Avila NA; Moss J; McCormack FX;
    Chest; 2019 Feb; 155(2):288-296. PubMed ID: 29940164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
    Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
    Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea.
    Chang S; Choi JS; Leem AY; Lee SH; Lee SH; Kim SY; Chung KS; Jung JY; Kang YA; Kim YS; Lee JG; Paik HC; Shim HS; Lee EH; Park MS
    Sci Rep; 2022 May; 12(1):8260. PubMed ID: 35585116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of change in FEV
    Taveira-DaSilva AM; Julien-Williams P; Jones AM; Stylianou M; Moss J
    Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29519926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical course and outcomes in patients with lymphangioleiomyomatosis.
    Yoon HY; Kim HJ; Song JW
    Respir Res; 2022 Jun; 23(1):158. PubMed ID: 35717210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis.
    Lazor R; Valeyre D; Lacronique J; Wallaert B; Urban T; Cordier JF;
    Respir Med; 2004 Jun; 98(6):536-41. PubMed ID: 15191039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
    Xu W; Yang C; Cheng C; Wang Y; Hu D; Huang J; He Y; Wang J; Chen K; Yang L; Zhou W; Zhang T; Liu S; Dai J; Meng S; Li X; Yang Y; Wang ST; Feng R; Zhang W; Zhang H; Wang L; Tian X; Xu KF
    Chest; 2023 Jul; 164(1):137-148. PubMed ID: 36801466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.
    Steagall WK; Stylianou M; Pacheco-Rodriguez G; Moss J
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis.
    Matthew BP; Hasani AM; Chen YC; Pirooznia M; Stylianou M; Rollison SF; Machado TR; Quade NM; Jones AM; Julien-Williams P; Taveira-DaSilva A; Chen MY; Moss J; Wen H
    Chest; 2021 Jul; 160(1):199-208. PubMed ID: 33549601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease monitoring using lung function trajectory in lymphangioleiomyomatosis: assessment in two national cohorts.
    Johnson J; Stewart I; Johnson SR
    Thorax; 2023 Jan; 78(1):61-68. PubMed ID: 35710743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.
    Kato M; Kanehiro Y; Yoshimi K; Kodama Y; Sekiya M; Sato T; Takahashi K; Seyama K;
    Respir Investig; 2018 Nov; 56(6):480-488. PubMed ID: 30143460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis.
    Gopalakrishnan V; Yao J; Steagall WK; Avila NA; Taveira-DaSilva AM; Stylianou M; Chen MY; Moss J
    Chest; 2019 May; 155(5):962-971. PubMed ID: 30660784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry.
    Maurer JR; Ryu J; Beck G; Moss J; Lee JC; Finlay G; Brown K; Chapman J; McMahan J; Olson E; Ruoss S; Sherer S;
    J Heart Lung Transplant; 2007 Dec; 26(12):1293-9. PubMed ID: 18096481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
    Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database.
    Hayashida M; Yasuo M; Hanaoka M; Seyama K; Inoue Y; Tatsumi K; Mishima M;
    Respir Investig; 2016 May; 54(3):193-200. PubMed ID: 27108015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyst Ventilation Heterogeneity and Alveolar Airspace Dilation as Early Disease Markers in Lymphangioleiomyomatosis.
    Walkup LL; Roach DJ; Hall CS; Gupta N; Thomen RP; Cleveland ZI; McCormack FX; Woods JC
    Ann Am Thorac Soc; 2019 Aug; 16(8):1008-1016. PubMed ID: 31038987
    [No Abstract]   [Full Text] [Related]  

  • 18. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.
    Taveira-DaSilva AM; Stylianou MP; Hedin CJ; Hathaway O; Moss J
    Chest; 2004 Dec; 126(6):1867-74. PubMed ID: 15596686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
    Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
    Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
    Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
    Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.